

## Capecitabine and Oxaliplatin Therapy (XELOX)

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour	C18	00321a	Capecitabine CDS Oxaliplatin Hospital
Treatment of advanced or metastatic colorectal cancer	C18	00321b	Capecitabine CDS Oxaliplatin Hospital
Adjuvant stage II/III gastric adenocarcinoma post D2 gastrectomy	C18	00321c	Capecitabine CDS Oxaliplatin Hospital

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Oxaliplatin is administered on day 1 and capecitabine is taken twice daily for two weeks (days 1-14) followed by a 7 day rest period on days 15-21. This 21 day (3-week) period is considered a treatment cycle.

Adjuvant treatment: Treatment is recommended for 3 months (4 cycles) or 6 months (8 cycles) at the discretion of the prescribing consultant.

Treatment for metastatic disease is until disease progression or unacceptable toxicity develops.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	Oxaliplatin <sup>a</sup>	130mg/m <sup>2</sup>	IV infusion	500ml glucose 5% over 2hrs <sup>b</sup>	Every 21 days
1-14	Capecitabine	1000mg/m <sup>2</sup> Twice Daily <sup>c, d, e</sup>	PO with food	N/A	Every 21 days
<sup>a</sup> Oxaliplatin is incompatible with 0.9% NaCl. For oxaliplatin doses ≤ 104mg use 250ml glucose 5%.					
<sup>b</sup> Increase infusion rate time to 4 – 6 hours in case of laryngopharyngeal dysaesthesia reaction.					
<sup>c</sup> The dose to be administered should consider the available tablet strengths. Please refer to the NCCP DOSE BANDING TABLES <a href="#">Here</a> for capecitabine. Tablets should be swallowed whole with plenty of water with food or within 30 minutes of eating. Tablets should not be crushed or cut.					
<sup>d</sup> (total daily dose = 2000mg/m <sup>2</sup> )					
<sup>e</sup> See dose modifications section for patients with identified partial DPD deficiency.					

### ELIGIBILITY:

- Indications as above
- ECOG status 0-1
- Expected survival > 3 months

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 1 of 8
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a> This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a>		

## CAUTION:

Use with caution in patients with clinically significant cardiovascular disease

## EXCLUSIONS:

- Hypersensitivity to capecitabine, oxaliplatin or any of the excipients
- Known complete DPD deficiency
- Pregnancy and lactation
- Severe leucopenia, neutropenia or thrombocytopenia
- Severe hepatic impairment
- Severe renal impairment (creatinine clearance below 30ml/min [Cockcroft and Gault] at baseline)
- Peripheral neuropathy with functional impairment prior to first cycle

## PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- INR tests if patient is on warfarin as clinically indicated
- DPD testing prior to first treatment with capecitabine using phenotype and/or genotype testing unless patient has been previously tested

### Regular tests:

- FBC, renal and liver profile prior to each cycle
- INR tests if patient is on warfarin as clinically indicated

### Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency.
  - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a Consultant.
- Toxicity due to capecitabine administration may be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction).
- Once the dose has been reduced, it should not be increased at a later time.
- For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption.
- Patients taking capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs.
- Doses of capecitabine omitted for toxicity are not replaced.

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 2 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Haematological:

Patients with baseline neutrophil counts  $< 1.5 \times 10^9/L$  and/or platelet counts of  $< 100 \times 10^9/L$  should not be treated with capecitabine.

**Table 1: Dose reduction levels for oxaliplatin and capecitabine for non-neurologic toxicity**

Drug	Dose	Dose -1	Dose-2	Dose-3
Oxaliplatin	130 mg/m <sup>2</sup>	100 mg/m <sup>2</sup>	85 mg/m <sup>2</sup>	Discontinue
Capecitabine	1000mg/m <sup>2</sup> BD	750 mg/m <sup>2</sup> BD	500 mg/m <sup>2</sup> BD	Discontinue

**Table 2: Dose Modifications for Haematological Toxicity**

Prior to a Cycles (DAY 1)	TOXICITY		Dose Level for Subsequent Cycles	
	Grade	ANC (x 10 <sup>9</sup> /L)	Oxaliplatin	Capecitabine
<ul style="list-style-type: none"> <li>If ANC <math>&lt; 1.2</math> on Day 1 of cycle, hold treatment, weekly FBC, maximum of 2 times</li> <li>ANC <math>\geq 1.2</math> within 2 weeks, proceed with treatment at the dose level noted across from the lowest ANC result of the delayed week(s).</li> <li>If ANC remains <math>&lt; 1.2</math> after 2 weeks discontinue treatment</li> </ul>	1	$\geq 1.2$	Maintain dose level	Maintain dose level
	2	1-1.19	Maintain dose level	Maintain dose level
	3	0.5-0.99	↓ 1 dose level	↓ 1 dose level
	4	$< 0.5$	↓ 2 dose levels	↓ 2 dose levels
	Grade	Platelets (x10 <sup>9</sup> /L)	Oxaliplatin	Capecitabine
<ul style="list-style-type: none"> <li>If platelets <math>&lt; 75</math> on Day 1 of cycle, hold treatment, weekly FBC, maximum of 2 weeks</li> <li>Platelets <math>\geq 75</math> within 2 weeks, proceed with treatment at the dose level noted across from the lowest platelets result of the delayed week(s).</li> <li>If platelets remains <math>&lt; 75</math> after 2 weeks discontinue treatment</li> </ul>	1	$\geq 75$	Maintain dose level	Maintain dose level
	2	50-74.9	Maintain dose level	Maintain dose level
	3	10-49.9	↓ 1 dose level	↓ 1 dose level
	4	$< 10$	↓ 2 dose levels	↓ 2 dose levels

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 3 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Renal and Hepatic Impairment:

**Table 3: Dose modification of capecitabine in renal and hepatic impairment**

Drug	Renal Impairment		Hepatic Impairment
	CrCl (ml/min)	Dose	
Capecitabine*	≥30	100% dose	In the absence of safety and efficacy data in patients with hepatic impairment, capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis.
	<30	Discontinue treatment	
Oxaliplatin	>30	Treat at normal dose and monitor renal function	Little information available. Probably no dose reduction necessary. Clinical decision.
	<30	Contraindicated	

\*Reference Table 5 for dose modification of capecitabine in treatment related hepatotoxicity

## Management of adverse events:

### Non-Haematological and Non-neurological Toxicities:

If Grade 2, 3 or 4 toxicities occur, daily administration of capecitabine should be immediately interrupted until these symptoms resolve or decrease in intensity to grade 1.

**Table 4: Dose Modifications for Non-Haematologic, Non-Neurologic Toxicity**

Prior to a Cycle (Day 1)	Grade **		Dose Level for Subsequent Cycles	
			Oxaliplatin	Capecitabine
<b>Diarrhoea</b> <ul style="list-style-type: none"> <li>If diarrhoea grade 2 on Day 1 of any cycle, hold treatment. Perform weekly checks maximum 2 times.</li> <li>If diarrhoea &lt; Grade 2 within 2 weeks, proceed with treatment at the dose level noted across from the Highest grade experienced.</li> <li>If diarrhoea remains Grade 2 after 2 weeks, discontinue treatment.</li> </ul>	1	Increase of < 4 stools/day over baseline	Maintain dose level	Maintain dose level
	2	Increase of 4 to 6 stools/day over baseline	Maintain dose level	Maintain dose level
	3	Increase of ≥7 stools/day	Maintain dose level	↓ 1 dose level
	4	<sup>a</sup> Increase of 10 or more stools/day or grossly bloody diarrhoea; may require parenteral support. Urgent intervention indicated	↓ 1 dose level	↓ 2 dose levels*
<b>Stomatitis</b> <ul style="list-style-type: none"> <li>If stomatitis ≥ Grade 2 on Day 1 of any cycle, hold treatment. Perform weekly checks, maximum 2 times.</li> <li>If stomatitis &lt; Grade 2 within 2 weeks, proceed with treatment at the dose level noted across from the highest Grade experienced.</li> <li>If stomatitis remains ≥Grade 2 after 2 weeks, discontinue treatment.</li> </ul>	1	Asymptomatic or mild symptoms; intervention not indicated	Maintain dose level	Maintain dose level
	2	Moderate pain or ulcer that does not interfere with oral intake; modified diet indicated	Maintain dose level	Maintain dose level
	3	Severe pain; interfering with oral intake	Maintain dose level	↓ 1 dose level
	4	<sup>a</sup> As above but mucosal necrosis and/or requires enteral support, dehydration. Urgent intervention indicated	↓ 1 dose level	↓ 2 dose levels*

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 4 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)	Grade **		Oxaliplatin	Capecitabine
<ul style="list-style-type: none"> <li>If hand-foot skin reaction <math>\geq</math> Grade 2 on Day 1 of any cycle, hold treatment. Perform weekly checks, maximum 2 times.</li> <li>If hand-foot skin reaction is <math>&lt;</math> Grade 2 within 2 weeks, proceed with treatment at the dose level noted across from the highest Grade experienced</li> <li>If hand-foot skin reaction remains <math>\geq</math> Grade 2 after 2 weeks, discontinue treatment.</li> </ul>	1	Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain	Maintain dose level	Maintain dose level
	2	Skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting instrumental ADL	Maintain dose level	Maintain dose level
	3	Severe skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting self care ADL	Maintain dose level	↓ 1 dose level

**\*If treatment with capecitabine is discontinued, then oxaliplatin is also discontinued. \*\*AE Grading CTCAEv5**

## Treatment related hepatotoxicity

**Table 5: Dose modification of capecitabine in treatment related hepatotoxicity**

Bilirubin		ALT, AST	Dose Modification
$> 3 \times$ ULN	or	$> 2.5 \times$ ULN	Withhold treatment until bilirubin decreases to $\leq 3.0 \times$ ULN or ALT, AST decrease to $\leq 2.5 \times$ ULN

## OXALIPLATIN

### Neurologic Toxicity

**Table 6: Dose reduction levels for oxaliplatin for Neurologic Toxicity**

Drug	Dose	Dose -1	Dose-2	Dose-3
Oxaliplatin	130 mg/m <sup>2</sup>	100 mg/m <sup>2</sup>	65 mg/m <sup>2</sup>	Discontinue

*If patient has both neurologic and non-neurologic toxicity, the final dose of oxaliplatin is the LOWER of the dose adjustments (i.e. if haematologic toxicity mandates dose -2 reduction (85 mg/m<sup>2</sup>) and neurologic toxicity mandates dose -2N reduction (65 mg/m<sup>2</sup>), then 65 mg/m<sup>2</sup> is given*

**Table 7: Dose Modifications for Neurologic Toxicity**

Toxicity Grade	Duration of Toxicity		Persistent (present at start of next cycle)
	1-7 days	$> 7$ days	
1	Maintain dose level	Maintain dose level	Maintain dose level
2	Maintain dose level	Maintain dose level	↓ 1 neurotoxicity dose level
3	↓ 1 neurotoxicity dose level	↓ 1 neurotoxicity dose level	Discontinue therapy
4	Discontinue therapy	Discontinue therapy	Discontinue therapy
Laryngo-pharyngeal dysaesthesia	Increase infusion time from 2 to 6 hrs	N/A	N/A

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 5 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## SUPPORTIVE CARE:

### EMETOGENIC POTENTIAL:

- Oxaliplatin - Moderate (**Refer to local policy**).
- Capecitabine - Low-Minimal (**Refer to local policy**).

**PREMEDICATIONS:** Not usually required unless patient has had a previous hypersensitivity.

### OTHER SUPPORTIVE CARE:

Medication may be required for management of diarrhoea, e.g. loperamide (4mg at first onset followed by 2mg after each loose stool (max 16 mg /day) or see local policy.

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

*The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.*

- **Diarrhoea and dehydration:** This may be dose limiting. Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Cardiotoxicity:** Angina-like chest pain, tachycardia, arrhythmias, heart failure, myocardial infarction and cardiac arrest may occur with capecitabine especially in patients with a prior history of coronary artery disease.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS),** also known as palmar-plantar erythrodysesthesia (PPE), is a common side effect associated with capecitabine (see Table 4 for dose modification of capecitabine for HFS).
- **Laryngopharyngeal dysaesthesia:** An acute syndrome of laryngopharyngeal dysaesthesia occurs in 1% - 2% of patients and is characterised by subjective sensations of dysphagia or dyspnoea/feeling of suffocation, without any objective evidence of respiratory distress (no cyanosis or hypoxia) or of laryngospasm or bronchospasm. Symptoms are often precipitated by exposure to cold. Although antihistamines and bronchodilators have been administered in such cases, the symptoms are rapidly reversible even in the absence of treatment. Prolongation of the infusion helps to reduce the incidence of this syndrome.
- **Extravasation:** Oxaliplatin causes irritation if extravasated (**Refer to local policy**).
- **Venous occlusive disease:** A rare but serious complications that has been reported in patients (0.02%) receiving oxaliplatin in combination with fluorouracil. This condition can lead to hepatomegaly, splenomegaly, portal hypertension and/or esophageal varices. Patients should be instructed to report any jaundice, ascites or hematemesis immediately.

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 6 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

- **Haemolytic Uremic Syndrome (HUS):** Oxaliplatin therapy should be interrupted if HUS is suspected: hematocrit is less than 25%, platelets less than 100,000 and creatinine greater than or equal to 135 micromol/L. If HUS is confirmed, oxaliplatin should be permanently discontinued.

## DRUG INTERACTIONS:

- Capecitabine enhances the anticoagulant effect of warfarin. Patients taking coumarin derivative anticoagulants should be monitored regularly for alterations in their coagulation parameters and the anti-coagulant dose adjusted accordingly.
- Sorivudine inhibits dihydropyrimidine dehydrogenase thus increasing its toxicity. Therefore, capecitabine must not be administered concomitantly with sorivudine or its chemically related analogues.
- Patients taking phenytoin or fosphenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
- Current drug interaction databases should be consulted for more information.

## REFERENCES:

1. Haller DG, Tabernero J, Maroun, J. et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *J Clin Oncol* 2011;29(11):1465-1471.
2. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol* 2008;26(12):2006-2012
3. BCCA Protocol Summary for Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine (GIAJCAPOX) Mar 2018
4. Grothey A et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *N Engl J Med.* 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709. PMID: 29590544; PMCID: PMC6426127. Noh, S. H., S. R. Park, H. K. Yang, et al. 2014. "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial." *Lancet Oncol* 15(12):1389-1396.
5. Bang, Y. J., Y. W. Kim, H. K. Yang, et al. 2012. "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial." *Lancet* 379(9813):315-321.
6. Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. *Lancet Onco*/2019; 20:e201-08.
7. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V4 2022. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
8. HPRA Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 7 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

9. Capecitabine (Xeloda®) Summary of Product Characteristics. Accessed August 2020. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000316/WC500058151.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000316/WC500058151.pdf)
10. Oxaliplatin (Eloxatin®) Summary of Product Characteristics. Last updated: 23/04/2019. Accessed August 2020. Available at: [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA0540-148-001\\_23042019151332.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0540-148-001_23042019151332.pdf)

Version	Date	Amendment	Approved By
1	03/06/2016		Prof Maccon Keane
2	30/05/2018	Applied new NCCP regimen template, Amended wording in exclusions with respect to DPD deficiency, updated dosing in renal impairment and clarified toxicity criteria for diarrhoea, stomatitis and hand-foot syndrome	Prof Maccon Keane
3	07/09/2018	Added in the new indication 'Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy'	Prof Maccon Keane
4	12/02/2020	Updated treatment table for oxaliplatin administration Updated recommended dose modifications for oxaliplatin in renal impairment	Prof Maccon Keane
5	11/03/2020	Updated recommended dose modifications for capecitabine in renal impairment	Prof Maccon Keane
6	24/08/2020	Reviewed. Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia	Prof Maccon Keane
7	23/9/2022	Amended adjuvant treatment duration	Prof Maccon Keane

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

NCCP Regimen: Capecitabine / Oxaliplatin (XELOX) Therapy	Published: 03/06/2016 Review: 23/09/2025	Version number: 7
Tumour Group: Gastrointestinal NCCP Regimen Code: 00321	ISMO Contributor: Prof Maccon Keane	Page 8 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		